Is highly purified cannabidiol a treatment opportunity for drug‐resistant epilepsy in subjects with typical Rett syndrome and CDKL5 deficiency disorder?

Abstract Objective This study aimed to evaluate the efficacy and safety of adjunctive, highly purified Cannabidiol (Epidiolex®) in individuals with drug‐resistant epilepsy (DRE) due to genetically determined typical Rett Syndrome (RTT) and CDKL5 Deficiency Disorder (CDD). Methods We recruited subjec...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Aglaia Vignoli, Giulia Prato, Enrico Alfei, Irene Bagnasco, Alberto Danieli, Massimiliano Celario, Jacopo Favaro, Sara Matricardi, Francesca Felicia Operto, Alessandro Orsini, Davide Paolo Bernasconi, Nicola Pietrafusa, Emilia Ricci, Luca Manfredini, Giulia Balletto, Paolo Bonanni, Maria Paola Canevini, Valentina De Giorgis, Lino Nobili, Stefano Sartori, Miriam Nella Savini, Ilaria Viganò, Nicola Specchio
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Wiley 2025-08-01
Rangatū:	Epilepsia Open
Ngā marau:	cannabidiol CDKL5 deficiency disorder drug‐resistant epilepsy Rett syndrome
Urunga tuihono:	https://doi.org/10.1002/epi4.70078
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!